Ad is loading...
JSCVX
Price
$27.40
Change
+$0.38 (+1.41%)
Updated
Nov 22 closing price
VISVX
Price
$51.30
Change
+$0.69 (+1.36%)
Updated
Nov 22 closing price
Ad is loading...

JSCVX vs VISVX

Header iconJSCVX vs VISVX Comparison
Open Charts JSCVX vs VISVXBanner chart's image
Janus Henderson Small Cap Value T
Price$27.40
Change+$0.38 (+1.41%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$51.30
Change+$0.69 (+1.36%)
VolumeN/A
CapitalizationN/A
JSCVX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
JSCVX vs. VISVX commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JSCVX is a Buy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. JSCVX (1.5B). VISVX pays higher dividends than JSCVX: VISVX (1.90) vs JSCVX (0.64). JSCVX was incepted earlier than VISVX: JSCVX (37 years) vs VISVX (27 years). JSCVX is a more actively managed with annual turnover of: 44.00 vs. VISVX (16.00). JSCVX has a lower initial minimum investment than VISVX: JSCVX (2500) vs VISVX (3000). VISVX annual gain was more profitable for investors over the last year : 30.04 vs. JSCVX (21.77). VISVX return over 5 years is better than : 62.14 vs. JSCVX (26.03).
JSCVXVISVXJSCVX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence37 years27 years-
Gain YTD14.54017.71282%
Front LoadN/AN/A-
Min. Initial Investment2500300083%
Min. Initial Investment IRAN/AN/A-
Net Assets1.5B57.6B3%
Annual Yield % from dividends0.641.9034%
Returns for 1 year21.7730.0472%
Returns for 3 years5.4416.9232%
Returns for 5 years26.0362.1442%
Returns for 10 years4.37109.834%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EFXT9.240.20
+2.21%
Enerflex Ltd
RVSN0.440.01
+1.60%
Rail Vision Ltd
CAG27.170.05
+0.18%
Conagra Brands
FULC2.97-0.02
-0.67%
Fulcrum Therapeutics
KYMR43.51-0.54
-1.23%
Kymera Therapeutics